IO Biotech

IO Biotech ROE

Delisted·Sep 22, 2026

The Return on Equity (ROE) of IO Biotech (IOBT) as of Nov 20, 2026 is -203.11 %. In the previous year, Return on Equity (ROE) was -64.65 % — a change of 214.19% (lower).

ROE

-203.11 %

YoY

214.19%

Last updated:

In 2024, IO Biotech's return on equity (ROE) was -203.11 %, a 214.19% increase from the -64.65 % ROE in the previous year.

The IO Biotech ROE history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

ROE
Date
ROE
Jan 1, 2019
730.73 USD
Jan 1, 2020
-462.62 USD
Jan 1, 2021
-32.03 USD
Jan 1, 2022
-51.46 USD
Jan 1, 2023
-64.65 USD
Jan 1, 2024
-203.11 USD
The IO Biotech ROE history
YEARROEYoY
-203.11 %+214.19%
-64.65 %+25.62%
-51.46 %+60.67%
-32.03 %-93.08%
-462.62 %-163.31%
730.73 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

IO Biotech Stock analysis

What does IO Biotech do? IO Biotech, Inc. develops immune modulating cancer therapies using its T-win technology platform. The Company focuses on product candidates that target immunosuppressive proteins like IDO and PD-L1, aiming to disrupt tumor-induced immunosuppression. Its lead candidate, IO102-IO103, is designed to address multiple pathways regulated by these proteins. The firm's pipeline includes therapies leveraging T-win to target the tumor microenvironment (TME). IO Biotech's revenue model is based on the development and potential commercialization of its product candidates. The company generates income through partnerships with pharmaceutical firms for the development and licensing of its therapies. These partnerships are formed with entities interested in advancing immune modulating cancer treatments. The target market includes pharmaceutical companies seeking innovative cancer therapy solutions. The firm's technology platform, T-win, is central to its business strategy. By targeting key immunosuppressive proteins such as IDO and PD-L1, IO Biotech addresses a critical need in cancer treatment. Its lead product candidate, IO102-IO103, is positioned to disrupt multiple immunosuppressive pathways, offering a novel approach to cancer therapy. IO Biotech is one of the most popular companies on Eulerpool.

ROE Details

Decoding IO Biotech's Return on Equity (ROE)

IO Biotech's Return on Equity (ROE) is a fundamental metric evaluating the company's profitability relative to its equity. Calculated by dividing net income by shareholder's equity, ROE illustrates how effectively the company is generating profits from shareholders’ investments. A higher ROE represents enhanced efficiency and profitability.

Year-to-Year Comparison

Analyzing IO Biotech's ROE on a yearly basis aids in tracking its profitability trends and financial performance. An increasing ROE suggests enhanced profitability and value generation for shareholders, whereas a declining ROE may indicate issues in profit generation or equity management.

Impact on Investments

IO Biotech's ROE is instrumental for investors assessing the company's profitability, efficiency, and investment attractiveness. A robust ROE indicates the firm’s adeptness at converting equity investments into profits, thereby enhancing its appeal to potential and current investors.

Interpreting ROE Fluctuations

Changes in IO Biotech’s ROE can emanate from variations in net income, equity capital, or both. These fluctuations are scrutinized to evaluate management’s effectiveness, financial strategies, and the inherent risks and opportunities, aiding investors in making informed decisions.

Frequently Asked Questions about IO Biotech stock

Return on Equity (ROE) of IO Biotech is -203.11 % in 2024.

Return on Equity (ROE) of IO Biotech changed from -64.65 % to -203.11 %, representing a 214.19% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Return on Equity (ROE) IO Biotech since 2006 – with annual values, charts, and detailed analysis.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Return on Equity (ROE)'s IO Biotech with sector peers and the industry average to assess whether it is attractive.

To evaluate Return on Equity (ROE)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Return on Equity (ROE).

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Profitability — IO Biotech

All Key Metrics — IO Biotech